HFpEF vs HFrEF in Preclinical Research: Model Selection, Induction Methods, and Translational Endpoints

​Heart failure remains one of the most complex therapeutic areas in cardiovascular drug development. The distinction between HFpEF vs HFrEF is especially important during preclinical research because each condition involves different pathophysiology, clinical presentation, and translational challenges. Model selection directly influences how investigators evaluate efficacy, mechanism of action, and biomarker relevance before entering clinical studies.

Heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) cannot be approached using identical experimental strategies. Disease induction methods, functional endpoints, and comorbidity profiles differ significantly. A translationally relevant preclinical design must reflect those differences early in development.

Understanding the Biological Differences Between HFpEF vs HFrEF

HFrEF is primarily characterized by impaired systolic function. Left ventricular ejection fraction declines because the myocardium loses contractile capacity. Common drivers include myocardial infarction, ischemic injury, and dilated cardiomyopathy. Ventricular dilation and reduced cardiac output are central pathological features.

HFpEF presents a different challenge. Ejection fraction remains relatively preserved, but ventricular filling becomes impaired due to increased stiffness and diastolic dysfunction. Patients often present with multiple metabolic and inflammatory comorbidities. Hypertension, obesity, diabetes, renal dysfunction, and aging all contribute to disease progression.

These mechanistic differences affect how investigators design preclinical studies:

• HFrEF studies often focus on ventricular remodeling, fibrosis, and impaired contractility

• HFpEF studies typically emphasize systemic inflammation, endothelial dysfunction, microvascular impairment, and metabolic stress

The translational gap is historically wider in HFpEF because the disease is highly heterogeneous. Single-hit animal models rarely capture the clinical complexity observed in patients.

Selecting Appropriate Animal Models for HFpEF vs HFrEF

Model selection should align with the therapeutic hypothesis and intended clinical population. No single model reproduces all aspects of either condition. Investigators often combine several models to strengthen translational relevance.

HFrEF Models

HFrEF models are generally more established and reproducible. Common induction approaches include coronary artery ligation and pressure overload techniques.

Frequently used HFrEF models include:

• Myocardial infarction induced through left anterior descending coronary artery ligation

• Transverse aortic constriction (TAC) to generate pressure overload

• Doxorubicin-induced cardiomyopathy

• Genetic cardiomyopathy models

Myocardial infarction models are especially valuable for therapies targeting post-infarction remodeling and fibrosis. TAC models are useful when studying hypertrophy progression and systolic decline under chronic pressure stress.

Endpoints in HFrEF studies commonly include reduced ejection fraction, ventricular dilation, myocardial fibrosis, and impaired hemodynamics.

HFpEF Models

HFpEF models are inherently more difficult because the human disease is multifactorial. Researchers increasingly favor multi-hit approaches that incorporate aging and metabolic dysfunction.

Common HFpEF induction strategies include:

• High-fat diet combined with nitric oxide synthase inhibition

• Obesity and diabetic rodent models

• Hypertension-induced cardiac remodeling

• Aged animal models

• Combined metabolic and inflammatory stress protocols

The ZSF1 obese rat remains widely used because it develops obesity, insulin resistance, hypertension, and diastolic dysfunction. Multi-hit mouse models combining diet-induced obesity with hypertensive stimuli are also increasingly common.

HFpEF studies often prioritize:

• Diastolic dysfunction

• Left ventricular stiffness

• Exercise intolerance

• Pulmonary congestion

• Systemic inflammation

• Endothelial dysfunction

HFpEF vs HFrEF: Induction Methods and Study Design Considerations

Induction strategy influences disease severity, progression rate, and reproducibility. Surgical approaches may generate robust phenotypes, but they can also introduce procedural variability and acute inflammatory responses.

For HFrEF, surgical infarction models allow relatively rapid disease induction. However, infarct size variability can affect study consistency. Imaging confirmation and standardized surgical training are essential for reducing variability across cohorts.

Pressure overload models such as TAC require careful calibration because excessive constriction may produce acute decompensation instead of progressive remodeling.

HFpEF induction protocols generally require longer timelines. Chronic metabolic stress develops gradually and may better reflect clinical disease progression. Investigators should account for:

• Age-dependent effects

• Sex-specific responses

• Comorbidity interactions

• Longitudinal functional decline

Female animals are particularly important in HFpEF studies because the clinical condition is more prevalent in women. Historically, many cardiovascular studies relied heavily on male animals, limiting translational insight.

Study duration also matters. HFpEF phenotypes often require extended induction periods before measurable dysfunction emerges. Short studies may fail to capture disease maturation or chronic inflammatory remodeling.

Translational Endpoints That Improve Clinical Relevance

Endpoint selection is critical when evaluating translational potential. Conventional cardiac measurements alone may not adequately predict clinical efficacy.

For HFrEF, commonly used translational endpoints include echocardiographic assessment of ejection fraction, ventricular dimensions, invasive hemodynamics, fibrosis quantification, and circulating biomarkers such as natriuretic peptides.

HFpEF requires broader phenotyping strategies. Diastolic function measurements should include parameters such as E/e’ ratio, ventricular relaxation indices, and filling pressures. Exercise capacity testing can also improve translational value because functional limitation is a major clinical feature in HFpEF patients.

Additional translational endpoints may include:

• Pressure-volume loop analysis

• Pulmonary vascular remodeling

• Renal function biomarkers

• Inflammatory cytokine profiling

• Endothelial function assays

• Histopathologic fibrosis assessment

Biomarker integration is becoming increasingly important across both HFpEF and HFrEF programs. Multi-omics approaches, including transcriptomics and proteomics, can help identify mechanistic signatures associated with therapeutic response.

Strengthening Translational Confidence in Heart Failure Programs

Successful cardiovascular drug development depends on selecting models that reflect the intended patient population and therapeutic mechanism. Overreliance on simplified models can create misleading efficacy signals that fail during clinical translation.

A strong preclinical strategy for HFpEF vs HFrEF should integrate:

• Mechanistically appropriate induction methods

• Clinically relevant functional endpoints

• Longitudinal disease characterization

• Biomarker-supported translational analysis

At IPS Therapeutique, preclinical cardiovascular research programs are designed around translational relevance and validated in vivo disease models. The scientific team supports tailored efficacy and safety evaluations across heart failure, vascular biology, metabolic dysfunction, and inflammatory pathways. This approach helps sponsors generate decision-ready data that better aligns with clinical development goals.

​IPST uses double and triple-hit models to better recapitulate the complexity of HFpEF. These models combined metabolic imbalance with surgical interventions and hormonal challenges.

Ready to strengthen your heart failure drug development program with translationally relevant models? Contact the IPS Therapeutique team today to discuss customized preclinical study designs for HFpEF, HFrEF, and related cardiovascular conditions.